1-deoxynojirimycin has been researched along with Diabetes Mellitus, Type 2 in 111 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (9.01) | 18.7374 |
| 1990's | 24 (21.62) | 18.2507 |
| 2000's | 30 (27.03) | 29.6817 |
| 2010's | 37 (33.33) | 24.3611 |
| 2020's | 10 (9.01) | 2.80 |
| Authors | Studies |
|---|---|
| Codd, R; Liao, V; Lifa, T; Liu, J; Obando, D | 1 |
| He, X; Ma, K; Mei, Y; Sun, Z | 1 |
| Dong, Y; Han, A; He, L; Jia, Q; Ren, X; Xing, Y; Xiu, Z; Yang, L | 1 |
| Donovan, CM; Jokiaho, AJ; Winchester, M | 1 |
| Chen, JG; Lin, P; Peng, DY; Tang, DB; Tu, YG; Xiao, PJ; Yin, ZP; Yuan, E; Zeng, JC; Zhang, QF | 1 |
| Ampawong, S; Aramwit, P; Fongsodsri, K; Kanjanapruthipong, T; Reamtong, O; Rujimongkon, K; Thaipitakwong, T | 1 |
| Dong, Y; Guo, Q; Han, X; He, X; Jiang, H; Liu, H; Ren, X; Xiu, Z | 1 |
| Chai, T; Du, HY; Jiang, Y; Li, L; Xu, H; Zhang, Y | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Dong, YS; Li, X; Xing, Y; Xiu, ZL; Yu, N; Zhang, B; Zhuang, C | 1 |
| Doguchi, S; Hariya, N; Kondo, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Iftikhar, M; Lu, Y; Zhou, M | 1 |
| Chen, GH; Hu, F; Hu, XQ; Thakur, K; Wei, ZJ; Zhang, HB; Zhang, JG | 1 |
| Arasaki, O; Dai, K; Ikenaga, H; Inoue, Y; Ishihara, M; Kishimoto, S; Mori, Y; Niki, T; Node, K; Ogasawara, K; Oshiro, K; Sata, M; Shibata, Y; Shimabukuro, M; Takashima, A; Tanaka, A | 1 |
| Ishibashi, S; Kotani, K; Nagashima, S; Okada, K; Osuga, J; Ozaki, K; Takahashi, M; Yagyu, H; Yamazaki, H | 1 |
| Anno, T; Hashiramoto, M; Hirukawa, H; Kaku, K; Kanda-Kimura, Y; Kawasaki, F; Kimura, T; Matsuki, M; Mune, T; Shimoda, M; Tatsumi, F; Tawaramoto, K | 1 |
| Abe, H; Fujitani, Y; Hara, A; Ishibashi, K; Kanazawa, A; Kawamori, R; Komiya, K; Ogihara, T; Tamaki, M; Uchida, T; Watada, H | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Fuchigami, M; Goda, T; Hariya, N; Inoue, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Ji, DF; Li, YG; Lin, TB; Lv, ZQ; Zhong, S | 1 |
| Horikawa, Y; Mikada, A; Narita, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Kishimoto, M; Noda, M | 2 |
| Bahtiyar, G; Ezeji, GC; Inoue, T; Sacerdote, A | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Li, C; Li, X; Liu, Q; Peng, G; Zheng, Y | 1 |
| Aoki, K; Shibata, E; Taguri, M; Tajima, K; Terauchi, Y | 1 |
| Goto, M; Hariya, N; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Babu, RJ; Dash, RP; Srinivas, NR | 1 |
| Aoki, K; Nakajima, S; Nezu, U; Shinoda, K; Terauchi, Y | 1 |
| Inoue, T; Node, K; Yokoyama, H | 1 |
| Fujita, H; Hosoba, M; Katsuura, Y; Morii, T; Narita, T; Sato, T; Yamada, Y | 1 |
| Adelman, MH; Monte, SV; Paladino, JA; Schentag, JJ | 1 |
| Aoki, K; Masuda, K; Miyazaki, T; Terauchi, Y; Togashi, Y | 1 |
| Daida, H; Fukao, K; Fukushima, Y; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miida, T; Miyazaki, T; Ohmura, H; Ohsaka, H; Shimada, K; Sumiyoshi, K | 1 |
| Kawamori, R; Nemoto, M; Tajima, N | 1 |
| Fuchigami, M; Fukaya, N; Goda, T; Inoue, S; Mochizuki, K; Muramatsu, T; Osonoi, T; Saito, M | 1 |
| Abiko, A; Araki, S; Haneda, M; Itoh, H; Koya, D; Maegawa, H; Nakagawa, A; Nishizawa, M; Uzu, T; Yokomaku, Y; Yokoyama, H | 1 |
| Chou, CW; Chu, CH; Hsieh, SH; Shih, KC | 1 |
| Deshpande, MC; Gadewar, ST; Mantri, AH; Venkateswarlu, V | 1 |
| Morimoto, A; Nishimura, R; Tajima, N; Taki, K; Tsujino, D; Utsunomiya, K | 1 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
| Emoto, T; Hashimoto, M; Iwasaki, M; Kageyama, H; Kim, SK; Matsuo, Y; Mizoguchi, T; Mizuguchi, T; Motodi, Y; Okamoto, H; Sawada, T; Taira, K; Takarada, A; Terashita, D; Yokoyama, M | 1 |
| Fujita, H; Hosoba, M; Morii, T; Narita, T; Sato, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Fukuda, H; Fuse, J; Ishii, S; Katabami, T; Kato, H; Kobayashi, H; Kobayashi, S; Kondo, A; Nagai, Y; Ohmori, S; Ohta, A; Sada, Y; Tanaka, Y | 1 |
| Matsuura, K; Mori, Y; Nakamura, A; Utsunomiya, K; Yokoyama, J | 1 |
| Fujii, M; Ichikawa, M; Imagawa, M; Inaba, S; Kimura, T; Konoshita, T; Miyamori, I; Sato, S; Suzuki, J; Takahashi, S; Zenimaru, Y | 1 |
| Fuchigami, M; Furuta, S; Hamada, Y; Nagasaki, H; Nakamura, J; Oiso, Y; Seino, Y | 1 |
| Drent, ML; Hoenderdos, EB; Jonker, JJ; Tollefsen, AT; van der Veen, EA; van Heusden, FH | 1 |
| Horowitz, M; Lee, A; Morley, JE; Patrick, P; Wishart, J | 1 |
| Artés, M; Benito, P; Faure, E; García-Mayor, R; López, JS; Mesa, J; Pallardo, LF; Puig-Domingo, M; Ravella, R | 1 |
| Chawla, S; Takiya, L | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Scheen, AJ | 1 |
| Aller, R; Conde Valentín, R; de Luis Román, DA; del Pozo García, E; Romero Bobillo, E | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Fehmann, HC | 4 |
| Akkermans, RP; Lucassen, PL; Rutten, GE; Van de Laar, FA; Van de Lisdonk, EH; Van Weel, C | 1 |
| Hayashi, I; Kuboyama, N; Yamaguchi, T | 1 |
| Aoki, K; Ito, S; Iwasaki, T; Kimura, M; Nakamura, A; Nezu, U; Takahashi, M; Terauchi, Y | 1 |
| Ishimura, I; Kannno, S; Node, K; Yokoyama, H | 1 |
| Baliga, VP; Jayaram, S; Kinagi, S; Mishra, AB; Periyandavar, I; Rajadhyaksha, GC; Sharma, A; Singh, KP | 1 |
| Ahn, YR; Kim, JH; Kim, KW; Kong, WH; Oh, SH; Seo, SW | 1 |
| Bozza, M; Corgiat-Mansin, L; Cravero, F; Giorda, C; Marena, S; Pagano, G; Rossi, CM | 1 |
| Branolte, JH; Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP; Wolffenbuttel, BH | 1 |
| Coniff, RF; Hoogwerf, BJ; Johnston, PS; Krol, A; Pi-Sunyer, FX; Santiago, JV | 1 |
| DeBouno, JF; Michaelis, OE; Tulp, OL | 1 |
| Johnson, AB; Taylor, R | 1 |
| Campillo, JE; Martinez, IM; Nieto, M; Ropero, MF; Tormo, MA | 2 |
| Berlin, C; Feig, PU; Petzinna, D; Ratzmann, KP; Rybka, J; Schernthaner, G; Segal, P | 1 |
| Coniff, RF; Davidson, JA; Feig, PU; Haffner, SM; Johnston, PS; Krol, A | 1 |
| Coniff, RF; Feig, PU; Johnston, PS; Kelley, DE; Krol, A; Mooradian, AD | 1 |
| Coniff, RF; Johnston, PS; Lebovitz, HE; Munera, CL; Raskin, P; Simonson, DC | 1 |
| Bauer, RJ; Mitrakou, A; Raptis, AE; Raptis, SA; Schulz, H; Tountas, N | 1 |
| Chiasson, JL; Rabasa-Lhoret, R | 1 |
| Lardinois, CK | 1 |
| Axen, KV; Li, X; Sclafani, A | 1 |
| Andres, E; Blicklé, JF; Brogard, JM | 1 |
| Riddle, MC | 1 |
| Scott, LJ; Spencer, CM | 1 |
| Stadler, HJ | 1 |
| Kuritzky, L; Quillen, DM; Samraj, G | 1 |
| Carlson, RF | 1 |
| Hanefeld, M; Naditch, L; Raptis, SA; Rybka, J; Schernthaner, G; Standl, E | 1 |
| Chiasson, JL; Naditch, L | 1 |
| Laws, A | 1 |
| Maislos, M; Rybka, J; Schernthaner, G; Segal, P; Van Gaal, L | 1 |
| Lefèbvre, PJ; Scheen, AJ | 1 |
| Neye, H | 1 |
| Kingma, PJ; Menheere, PP; Nieuwenhuijzen Kruseman, AC; Sels, JP | 1 |
| Ahrens, K; Arends, J; Lübke, D; Willms, B | 1 |
| Holman, RR; Steemson, J; Turner, RC | 1 |
| Bloom, SR; Requejo, F; Uttenthal, LO | 1 |
| Klauser, RM; Prager, RJ; Schernthaner, G; Schnack, C; Schneider, BG; Winkler, J | 1 |
| Heinz, G; Komjati, M; Korn, A; Waldhäusl, W | 1 |
| Hillebrand, I; Omar, MA; Seedat, MA | 1 |
| Scott, AR; Tattersall, RB | 1 |
| Alberti, KG; Samad, AH; Taylor, R; Ty Willing, TS | 1 |
| Federlin, K; Hillebrand, I; Laube, H | 1 |
| Bam, WJ; Joubert, PH; Manyane, N | 1 |
| Luger, A; Röggla, G; Schernthaner, G; Schnack, C | 1 |
| Anastasopoulou, K; Frangaki, D; Hillebrand, I; Katsilambros, N; Marangos, M; Philippides, P; Protopapas, J; Siskoudis, P; Toskas, A; Xefteri, H | 1 |
| Arends, J; Willms, BH | 1 |
15 review(s) available for 1-deoxynojirimycin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The many faces of the adamantyl group in drug design.
Topics: Adamantane; Animals; Antimalarials; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Iron Chelating Agents; Iron Overload; Malaria; Solubility | 2011 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Metformin; Prediabetic State | 2019 |
An overview of therapeutic potential of N-alkylated 1-deoxynojirimycin congeners.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Diabetes Mellitus, Type 2; Female; Swine | 2021 |
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
Therapeutic options for the management of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Diabetes Mellitus, Type 2; Disease Management; Education, Medical, Continuing; Education, Pharmacy, Continuing; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Aspart; Managed Care Programs; Metformin; Thiazoles; Thiazolidinediones; United States | 2002 |
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2005 |
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Body Weight; Cognition; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Trisaccharides | 1998 |
Type 2 diabetes: glycemic targets and oral therapies for older patients.
Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Piperidines; Sulfonylurea Compounds; Trisaccharides | 1998 |
[Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Topics: 1-Deoxynojirimycin; Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disaccharides; Drug Combinations; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hydrolysis; Hypoglycemic Agents; Imino Pyranoses; Insulin; Polysaccharides | 1999 |
Oral pharmacologic management of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; United States | 1999 |
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glucosamine; Glucosidases; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption; Liver; Postprandial Period; Randomized Controlled Trials as Topic; Tissue Distribution | 2000 |
Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Imino Pyranoses | 1999 |
[Reducing postprandial glucose levels. Glucosidase antagonists].
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucosidases; Humans; Hypoglycemic Agents; Imino Pyranoses; Postprandial Period | 2002 |
52 trial(s) available for 1-deoxynojirimycin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy.
Topics: 1-Deoxynojirimycin; Adult; Aged; Cytokines; Diabetes Mellitus, Type 2; Fasting; Female; Gene Expression Regulation; Hospitals, University; Humans; Hypoglycemic Agents; Inflammation; Leukocytes; Male; Middle Aged; Prospective Studies; RNA, Messenger; S100 Proteins | 2021 |
α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.
Topics: 1-Deoxynojirimycin; Acute Coronary Syndrome; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycoside Hydrolase Inhibitors; Heart Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2017 |
Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Isoindoles; Male; Metformin; Middle Aged; Prognosis | 2013 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Asian People; Blood Glucose; Cardiovascular Diseases; Chemokine CCL2; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Prospective Studies; Risk Factors; Time Factors | 2014 |
Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incretins; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Breakfast; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Tablets | 2016 |
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Pyrimidines; Treatment Outcome | 2016 |
Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Postprandial Period | 2008 |
Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance.
Topics: 1-Deoxynojirimycin; Aged; Benzamides; Cystatin C; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged | 2009 |
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Food; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kinetics; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic p
Topics: 1-Deoxynojirimycin; Aged; Coronary Artery Disease; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Inositol; Lipid Metabolism; Male; Middle Aged; Treatment Outcome | 2010 |
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Postprandial Period | 2011 |
Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds | 2011 |
Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Topics: 1-Deoxynojirimycin; Acarbose; Adult; Aged; alpha-Glucosidases; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Japan; Male; Middle Aged; Pilot Projects; Young Adult | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Inositol; Male; Middle Aged; Obesity; Postprandial Period | 2012 |
Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
Topics: 1-Deoxynojirimycin; Adult; Aged; Area Under Curve; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Male; Middle Aged; Postprandial Period; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Topics: 1-Deoxynojirimycin; Apolipoprotein A-I; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Lispro; Lipids; Lipoproteins, HDL; Male; Middle Aged; Postprandial Period; Treatment Outcome; Triglycerides | 2012 |
Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Food; Gastrointestinal Diseases; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Placebos | 2002 |
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Appetite; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Middle Aged; Obesity; Peptide Fragments; Postprandial Period; Protein Precursors | 2002 |
HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Diet, Diabetic; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Mediterranean Region; Postprandial Period; Regression Analysis | 2002 |
Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adiponectin; Albuminuria; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged | 2007 |
Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Pyranoses; India; Male; Middle Aged; Postprandial Period; Prospective Studies; Risk Factors; Treatment Outcome | 2007 |
Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Multivariate Analysis; Time Factors; Treatment Failure; Triglycerides | 1995 |
Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Male; Middle Aged | 1994 |
Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Lipids; Male; Middle Aged; Time Factors | 1994 |
Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Cholesterol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Female; Fructosamine; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Metabolic Clearance Rate; Middle Aged; Triglycerides | 1996 |
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Diet, Diabetic; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Flatulence; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Placebos; Postprandial Period | 1997 |
Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Topics: 1-Deoxynojirimycin; Albuminuria; Blood Glucose; Creatinine; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enzyme Inhibitors; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hispanic or Latino; Humans; Imino Pyranoses; Insulin; Lipids; Male; Middle Aged; Placebos; Postprandial Period; Time Factors; Treatment Outcome | 1998 |
Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Topics: 1-Deoxynojirimycin; Black People; Blood Glucose; Cholesterol, LDL; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Enzyme Inhibitors; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Placebos; Postprandial Period; Single-Blind Method; Sulfonylurea Compounds; Treatment Outcome; Triglycerides | 1998 |
Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Food; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Kinetics; Male | 1998 |
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Fasting; Female; Follow-Up Studies; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged; Postprandial Period; Time Factors | 1998 |
[Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin Resistance | 2000 |
Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Topics: 1-Deoxynojirimycin; Analysis of Variance; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Therapy, Combination; Female; Glucosamine; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Placebos | 2001 |
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fasting; Female; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Metformin; Middle Aged; Placebos; Postprandial Period; Racial Groups | 2001 |
Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Metformin; Middle Aged; Single-Blind Method | 2001 |
alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Fatty Acids, Nonesterified; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 1992 |
[Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Dietary Fiber; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Intestinal Absorption; Middle Aged | 1991 |
Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Eating; Female; Fructosamine; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin, Long-Acting; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Reference Values; Time Factors; Triglycerides | 1991 |
Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
Topics: 1-Deoxynojirimycin; Adult; Aged; Biomarkers; Blood Glucose; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Fiber; Double-Blind Method; Eating; Female; Fructosamine; Galactans; Glucosamine; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Imino Pyranoses; Male; Mannans; Middle Aged; Plant Gums; Random Allocation; Triglycerides | 1990 |
Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Liver; Male; Middle Aged | 1989 |
Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dose-Response Relationship, Drug; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Middle Aged; Time Factors | 1989 |
The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients.
Topics: 1-Deoxynojirimycin; Adult; Anti-Bacterial Agents; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Male; Middle Aged; Random Allocation; Sulfonylurea Compounds | 1987 |
Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Intestinal Absorption; Middle Aged; Random Allocation | 1988 |
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Female; Glucosamine; Glycerol; Glycoside Hydrolase Inhibitors; Humans; Hydroxybutyrates; Hypoglycemic Agents; Imino Pyranoses; Insulin; Lactates; Male; Middle Aged; Pyruvates | 1988 |
Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged; Obesity; Pancreatic Hormones | 1986 |
A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Tolerance; Female; Glucosamine; Humans; Imino Pyranoses; Male; Middle Aged; Random Allocation | 1986 |
Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Male; Middle Aged; Sulfonylurea Compounds | 1986 |
44 other study(ies) available for 1-deoxynojirimycin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[1-deoxynojirimycin alleviates liver fibrosis induced by type 2 diabetes in mice].
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Liver Cirrhosis; Mice; Mice, Inbred C57BL | 2021 |
Effect of 1-Deoxynojirimycin on insulin resistance in prediabetic mice based on next-generation sequencing and intestinal microbiota study.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Gastrointestinal Microbiome; High-Throughput Nucleotide Sequencing; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Morus; Prediabetic State; Streptozocin | 2022 |
N-Hydroxyethyl-1-Deoxynojirimycin (Miglitol) Restores the Counterregulatory Response to Hypoglycemia Following Antecedent Hypoglycemia.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Glucose Clamp Technique; Hypoglycemia; Hypoglycemic Agents; Insulin; Norepinephrine; Rats; Sodium | 2022 |
Chalcone-1-Deoxynojirimycin Heterozygote Reduced the Blood Glucose Concentration and Alleviated the Adverse Symptoms and Intestinal Flora Disorder of Diabetes Mellitus Rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Chalcone; Chalcones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Heterozygote; Hypoglycemic Agents; Rats | 2022 |
Mulberry-Derived 1-Deoxynojirimycin Prevents Type 2 Diabetes Mellitus Progression via Modulation of Retinol-Binding Protein 4 and Haptoglobin.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Haptoglobins; Humans; Inflammation; Insulin Resistance; Morus; Plant Extracts; Plant Leaves; Powders; Prediabetic State | 2022 |
Combinational application of the natural products 1-deoxynojirimycin and morin ameliorates insulin resistance and lipid accumulation in prediabetic mice.
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Type 2; Drug Combinations; Flavonoids; Insulin; Insulin Resistance; Lipids; Mice; PPAR gamma; Prediabetic State | 2023 |
Mulberry leaf multi-components exert hypoglycemic effects through regulation of the PI-3K/Akt insulin signaling pathway in type 2 diabetic rats.
Topics: 1-Deoxynojirimycin; Adipokines; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Morus; Phosphatidylinositol 3-Kinases; Plant Leaves; Polysaccharides; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2024 |
Dietary 5,6,7-Trihydroxy-flavonoid Aglycones and 1-Deoxynojirimycin Synergistically Inhibit the Recombinant Maltase-Glucoamylase Subunit of α-Glucosidase and Lower Postprandial Blood Glucose.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Flavonoids; Glucan 1,4-alpha-Glucosidase; Glycoside Hydrolase Inhibitors; Humans; Kinetics; Mice; Mice, Inbred C57BL; Morus; Plant Extracts; Plant Leaves; Postprandial Period | 2020 |
Metabolic Effect of 1-Deoxynojirimycin from Mulberry Leaves on db/db Diabetic Mice Using Liquid Chromatography-Mass Spectrometry Based Metabolomics.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Male; Mass Spectrometry; Metabolomics; Mice; Mice, Inbred C57BL; Morus; Plant Extracts; Plant Leaves | 2017 |
Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucose Tolerance Test; Hypoglycemic Agents; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Hypoglycemic effect of deoxynojirimycin-polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fructose-Bisphosphatase; Glucokinase; Glucosamine; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred ICR; Phosphoenolpyruvate Carboxykinase (ATP); Phosphofructokinase-1, Liver Type; Pyruvate Carboxylase; Pyruvate Decarboxylase; Random Allocation | 2015 |
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrimidines | 2015 |
Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism.
Topics: 1-Deoxynojirimycin; Aged; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glycoside Hydrolase Inhibitors; Hallucinations; Humans; Hypoglycemic Agents; Hypothyroidism; Renal Insufficiency, Chronic | 2015 |
1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice.
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Morus; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphorylation; Plant Extracts; Plant Leaves; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction | 2015 |
Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inositol | 2018 |
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Postprandial Period | 2009 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dietary Carbohydrates; Energy Intake; Follow-Up Studies; Gluconeogenesis; Glucose; Glycated Hemoglobin; Heart Diseases; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Intestinal Absorption; Liver; Metformin; Myocardial Infarction; Thiazolidinediones | 2010 |
The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Base Sequence; Cytokines; Diabetes Mellitus, Type 2; DNA Primers; Enzyme Inhibitors; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Leukocytes | 2010 |
Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Interleukin-18; Postprandial Period | 2011 |
Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Biological Availability; Blood Glucose; Cellulose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dogs; Drug Implants; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Intestine, Small; Male; Methylcellulose; Polymers; Postprandial Period; Rats; Rats, Sprague-Dawley | 2011 |
Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Brachial Artery; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Endothelium, Vascular; Female; Follow-Up Studies; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome; Ultrasonography; Vasodilation | 2012 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Topics: 1-Deoxynojirimycin; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Prospective Studies; Retrospective Studies | 2012 |
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Topics: 1-Deoxynojirimycin; Animals; Bile Acids and Salts; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Obesity; Rats; Rats, Wistar | 2013 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[Usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose].
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosamine; Humans; Hyperlipidemias; Hypoglycemic Agents; Imino Pyranoses; Lipids; Male; Middle Aged; Treatment Outcome | 2004 |
[Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Family Practice; Feasibility Studies; Female; Follow-Up Studies; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Internal Medicine; Male; Middle Aged; Patient Compliance; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Weight Loss | 2000 |
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Safety; Time Factors; Triglycerides | 2001 |
[Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Topics: 1-Deoxynojirimycin; Animals; Diabetes Mellitus, Type 2; Dogs; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Rats | 2006 |
Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Enzyme Inhibitors; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 2007 |
Antiobesity effects and improvement of insulin sensitivity by 1-deoxynojirimycin in animal models.
Topics: 1-Deoxynojirimycin; Animals; Anti-Obesity Agents; Blood Glucose; Bombyx; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Insulin; Insulin Resistance; Male; Rats; Rats, Inbred OLETF; Rats, Sprague-Dawley; Weight Gain | 2008 |
The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Male; Obesity; Rats; Rats, Inbred SHR | 1993 |
In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; In Vitro Techniques; Intestinal Absorption; Intestine, Small; Male; Perfusion; Rats; Rats, Wistar | 1996 |
Effect of miglitol administration to non-insulin-dependent diabetic rats.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Enzyme Inhibitors; Glucosamine; Hypoglycemic Agents; Imino Pyranoses; Male; Rats; Rats, Wistar | 1998 |
Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Topics: 1-Deoxynojirimycin; Animal Feed; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucosamine; Glucose; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Secretion; Islets of Langerhans; Obesity; Rats; Rats, Sprague-Dawley; Ventromedial Hypothalamic Nucleus | 1999 |
Miglitol for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 1999 |
[Drug therapy of type 2 diabetes: insulin sensitizers improve results].
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Diet Therapy; Diet, Diabetic; Drug Therapy, Combination; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin | 1999 |
[Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses | 2000 |
Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Liver; Liver Function Tests; Transaminases | 2000 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
[Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Topics: 1-Deoxynojirimycin; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Energy Metabolism; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 2001 |
Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Topics: 1-Deoxynojirimycin; Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Intestinal Absorption | 2002 |
Effect of alpha-inhibitors on blood glucose and insulin levels.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Middle Aged; Obesity; Reference Values; Trisaccharides | 1988 |
Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Anti-Bacterial Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosamine; Humans; Imino Pyranoses; Insulin; Male; Middle Aged | 1986 |